A high percentage of patients with leukemia, lymphoma, and solid tumors achieve a
complete clinical remission after initial treatment, but the majority of these patients will finally …

The appropriate management of haematological disorders must rely on a precise and long-
term monitoring of the patient's response to chemotherapy and radiotherapy. Clinical data …

The appropriate management of haematological disorders must rely on a precise and long-
term monitoring of the patient's response to chemotherapy and radiotherapy. Clinical data …

Minimal residual disease (MRD) can be detected in many patients with leukemia who have
achieved complete remission as defined by conventional pathology examination. The …

BACKGROUND: The detection of malignant cells by quantitative real-time PCR has become
state of the art for diagnosis, monitoring response to treatment and detection of minimal …

The term 'minimal residual disease'(MRD) defines the level of disease detectable in patients
in clinical remission during therapy, below the detection limit of conventional methods. Very …

Over the past two decades substantial progress has been made in the therapy of human
leukemias. This development can be illustrated by the success in the treatment of the most …

Simple Summary Minimal/measurable residual disease (MRD) monitoring is a powerful and
independent predictor of outcomes in both children and adult acute lymphoblastic leukemia …

Minimal residual disease (MRD) is the tumor burden that is present after a course of
treatment that has resulted in clinical remission. For hematopoietic malignancies, techniques …

The analysis of minimal residual disease (MRD) has assumed a growing role in the follow-
up of patients with acute lymphoblastic leukemia (ALL). We have applied multiparameter …